newsfilter
← Latest News
Business Wire·

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

- Strategic partnership, announced in July 2025, utilizes JCR's J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer's disease - Option exercise